Introduction
Epidemiologicalo bservationst hatadietr ichi nsoyis associated withalowerincidenceofmenopausalsymptoms,osteoporosis,cardiovasculardisorders and uterus, breast and colon cancerin Asianp opulationsincreased the interest in phyto-oestrogensin menopausalwomen [1] .
The useo fn aturaln on-steroidalsubstancesextracted from soyt ocontrol menopausalsymptomsisimportant,asitavoidsthe adverseeffects of hormone replacementt herapyt hankst otheirpotencybeing 1000 to 10,000 timeslowert hanthatof oestradiol,whosestructuretheymimic.
Soyisoflavonesarethe class of phyto-oestrogenswith the greatest effecton menopausalsymptoms.Theyare presentin soyand areattached tocarbohydrates(glycosides) [2] .Theyareabsorbed att he intestinall evel only if hydrolyzed toaglycones(genistein,daidzein and its metabolite,equol) byglycosidases,enzymesproduced byt he intestinalf lora, and in particularbylactobacilli [3] .Itfollows thatcertain situations,suchast he useo f antibioticsors ome diseasest hatr educethe number and activity of the intestinalf lora, canadverselyinfluencethe absorption and action of isoflavones,which areo nthe otherhand similarlyabsorbed in pre-and post-menopausalwomen [4] .
Theseconsiderations,therefore,formed the basicrationale tod evelop afood supplementin the formo f soyisoflavonesenriched with Lactobacillus sporogenes, apromoterof intestinalabsorption. The aim of this studyw ast overifyt he single dosebioavailability of an oralf ormulation of soyisoflavones,withand without L.sporogenes ,in menopausalwomen withg ut microfloradepletion duetoantibiotictherapy.
Abstract
Purposeo fthe study: Toverifyt he single dosebioavailability of twoo ralf ormulationsof soyisoflavones,withand without lactobacilli,in menopausalwomen in antibiotictherapy.
Methods The pharmacokineticstudyw asconducted in the Departmentof ClinicalPharmacologyand Therapeutics,U MHAT "Queen Joanna",S ofia, Bulgaria-Second MBAL, Clinicof Cardiology,S ofia, Bulgaria.Itw asapproved byt he locale thics committee atSecond MBAL Hospitaland the BulgarianDrug Agency(BDA)and carried out in accordancewiththe Helsinki Declaration and its revisionsand Good ClinicalPractice.
The inclusion criteriaincluded ab odyw eightw ithin 10%o f the idealbodyw eight(asdefined in the MetropolitanHeight and WeightTables),normalp hysicale xamination and laboratory evaluations,history of treatmentw ithp enicillin orother b -lactamantibioticswithout suffering anyallergicreaction.
The exclusion criteriawere:history of alcohol ordrugabuse, smoking morethanten cigarettes/day,history of serious gastrointestinal,renal,hepatic, pulmonary orcardiovasculardisease;orhistory of epilepsy,asthma, diabetes,psychosisorglaucoma, history of allergicresponsetosoyorr elated substances, participation in aprevious clinicaltrialwithin the past three months,b lood donation of 250ml ormorewithin the past three months,history of allergicreactionst oanypenicillin or b -lactamantibioticsin general,previous history of cholestatic jaundice/hepaticdysfunctionassociated withamoxicillin +cla-vulanica cid treatment,practising vegetarian,a bnormald iets (< 1600 or > 3500 kcal/day)o rs ubstantialchangesin eating habits within the past 4weeks,treatmentw ithanyknowne nzyme inhibiting orinducing agents (barbiturates,phenothiazines,c imetidine,etc.) within the past four weeks,positiveto drugsof abuse( qualitativescreen in urine),useo fanyprescription orover-the-countermedication on aregularbasis, drinking excessiveamounts of tea, cacao,c offee and/orbeveragescontaining caffeine (> 5cups/day)o rw ine (> 0.5 l/day orequivalents),orlikelytobenon-compliantoruncooperative during the study.Women on aspecificdiet(i. e. vegetarian) weren otadmitted tothe study,during whichn osoyfood was allowed. The volunteers wererequested nott otake anyprescription orover-the-countermedication foraperiod of atleast four weekspriort oand during the study(including the washout period),no alcoholicorcaffeine-containing beveragesfrom 48 hpriortoand until the last blood sampling time (24h)after eachadministration and toavoid yogurt and anyfood containing soyorits derivativesfrom 48 hp riort othe start of antibiotictreatmentand until the last blood sampling time after eachadministration. Moreover,a voidanceo ff reshg rapefruit orgrapefruitjuicef rom twoweekspriort oand during the entirep eriod of the study(possible hepaticenzyme induction) wasr equested.
Subjects wereh ospitalised in the ClinicalCentrei nthe evening of the daybeforetrialsubstanceadministration,a nd remained thereunderpermanentmedicaland nursing supervision for3 6hafteradministration in eachtreatmentperiod. Afterthe last administration,the physicalexamination,haematological,b iochemicaland urine analysesw ererepeated. Vital signsand ECG at2 4h afterdose,fort he second period,were considered the finalevaluation.
2.2Nutraceuticalp roducts
The test product(E)wasafood supplementin tablets containing soyisoflavones6 0mg (genistin 30 mg +daidzin 30 mg) + 500 million vitalsporesof L.sporogenes +calcium1 41 mg and vitamin D 3 5 l g( Estromineral Ò ,R ottapharmS.p.A.,M onza, Italy,F ood Supplements ItalianRegisterXAD 00462-Y, batch no. 507478) and the referencep roduct(R)wasafood supplementin tablets withthe same composition asEb ut without L.sporogenes (batchno. ES020/04prepared byRottapharm ï Madaus PharmaceuticalDevelopmentDepartment).
2.3Studydesign
Ac ontrolled,two-periodcross-overs tudyw ithrandomised sequencesw asplanned according toarepeated Latin Squares design.
Eachsubjectunderwenttwoperiodsof fivedays of antibiotic treatmentwithatwo-weekwash-out atthe end of eachperiod. Alternatively,asingle doseo fo ne of the twof ormulationsin random sequencewasgiven. Eand Rwereadministered in the morning of the 6 th dayof eachstudyperiod with200 ml of wateratr oom temperatureunderfasting conditions.The antibiotictreatmentw asr epresented byamoxicillin trihydrate corresponding toamoxicillin 875mg+potassiumclavulanate corresponding toclavulanica cid 125mg( Augmentin Ò ,G laxoSmithKline,V erona, Italy),three timesdailyforfived ays.For the morning dosing,subjects weren otallowed tod rink water from 1h beforeuntil 2hafteradministration,exceptt hat planned fort he drugadministration. Four hours aftermorning drugadministration,lunchwass erved. Aftert he last administration,physicale xamination,vitalsigns,E CG, haematological, biochemicaland urine analyseswererepeated.
Plasmawassampled attime 0(just beforedosing) and 1,1.5, 2,2.5,3,4,6,8,12and 24h afterdosing. Blood samples(approximately10ml) werecollected byani ndwelling catheter intoh eparinised test tubes,mixed bygentlyinvertingthem immediatelyafterblood withdrawaland rapidlycentrifuged at +4°C(1500 gf or10min). Resulting plasmawass eparated, transferred intop olypropylene tubes,stoppered (airtight)and immediatelyfrozen at-20°Cuntil assayed.
Analysisof plasmasamples
Genistein,daidzein and equol wereanalysed in plasmab ya validated LC-MS/MS method afterenzymatichydrolysisw ith b -glycuronidaseand aryl-sulphatesbyBT Biotecnica Laboratory,V arese,I taly,in compliancewithGLP rules,a sr equested byt he CPMP Guidanceo nthe Investigation of Bioavailability and BioequivalenceofJuly2 001.
Calibration curvesw erel inearin the range of 5-1000 ng/ml withacoefficientof correlation of r ! 0.999 forgenistein,daidzein and equol. The lowerlimitof quantification was5ng/ml, the precisionwas5.8 %forgenistein,5.3%fordaidzein and 5.9 forequol,a nd the accuracyw as115 %f orgenistein,105% for daidzein and 88 %forequol.
Intra-assayprecision of quality control samples(expressed asacoefficientof variation) was=2.10%forgenistein,=4.01% fordaidzein and 3.34% forequol. Intra-assayaccuracyr anged from 95 to1 11 %f orgenistein,from 101to1 11 %f ordaidzein and from 98 to1 07 %forequol.
Propyl-4-hydroxybenzoate( Sigma-Aldrich,M ilan,I taly)was used asinternalstandard.
Aliquots of plasmaextract(50 l l) weresubjected toLC-MS/ MS on aS himadzu system 10AD class-VP, consisting of ab inary pump,a utosamplerat4°C, column at2 5°C, detectorUV/ 
Pharmacokinetica nalysis
The individualtime coursesof plasmac oncentrationsw ere analysed according toanon-compartmentalapproachusing the Kinetica # software( Innaphase). The pharmacokinetic parameters assessed were:C max ,t max ,AUC 0-24 ,t 1/2 ,MRT.Maximump lasmac oncentration( C max )and the time of maximum plasmac oncentration (T max )wered erived from the plasma concentration-time curve. The areaundert he plasmac oncentration-timecurve,from the time zerotothe last measurable concentration( AUC 0-t )wascalculated byt he trapezoidalrule, setting tozerothe valuesbelowthe limitof quantification. The areaunderthe plasmaconcentration-time curvefrom the time zerotoinfinity (AUC 0-1 )wasestimated byextrapolating toinfinity AUC 0-t .The apparentterminalrateconstant( k z )wasobtained ast he slope ln-linearregression analysisof plasmaconcentration-time curvesin the terminalp hase. The apparent terminalh alf-life (T 1/2 )wascalculated as:T 1/2 =ln(2)/ k z .The meanresidencetime (MRT)wascalculated ast he ratio between AUMC and AUC, whereAUMC ist he areaundert he plasmac oncentration · time vs. time curve. The pharmacokineticbioequivalenceofthe formulationsw asassessed bycomparing C max and AUC.
2.6Statisticalanalysis
The statisticalanalysisw asperformed withthe Kinetica software( InnaPhase) byanalysisof variance( ANOVA)o nC max , and AUC logarithmicallyt ransformedd ata, and on non-transformed MRT data.T max wasanalysed byt he non-parametric Friedmantest.Inp articular,the bioequivalencecalculation wasbased on the 90%symmetricalconfidencei nterval( CI) fort he log-transformed dataof AUC 0-24 and C max within the range of 80-125% fort he ratio E/R.The twoo ne sided t-test wasu sed.
3.Results
The meanplasmaconcentrationsof genistein and daidzein afteroraladministration of the twoi soflavone formulationsareshowninFig. 1and 2.The valuesof equol werebelowt he limitof quantification.
The main pharmacokineticparameters arereported in Tables1and 2.
Genistein pharmacokineticparameters wereh igher afterEthanafterRa dministration and the differences between formulationsw erem orethan20 %f orC max (+ 24.3%),a nd forAUC 0-24 (+ 24.4 %) and less than 20 %f orMRT (+ 11.0%). The 90%confidencei nterval fort he ratio E/Rwasoutside the bioequivalenceacceptancel imits (0.80-1.70 forC max and 0.84 -1.70 for AUC 0-24 ).
Daidzein pharmacokineticparameters C max and AUC showed awiderv ariability on R, evidenced byhigher scattering from the meano nthe formulation without L.sporogenes :A UC standarde rrorof the mean( SEM) was14 %forEa nd 27 %forR.
Nosignificantalterationsof physiologicalf unctions wereo bserved versus baseline and alsobetween formulations.Noadversee vents weren oted during the study and no abnormall aboratory valuesw eref ound after eithert reatmentr egimen withthe twoi soflavone formulations.
Discussion
The meanp lasmac urvep rofilesof genistein and the derived pharmacokineticparameters obtained in this kineticstudyafteroraladministration of isoflavones withand without L.sporogenes showed thatbioequivalencebetween Ea nd Rformulationscann otbestated ast he 90%confidencei ntervalsfort he AUC and C max werem orethan20 %differentfrom eacho ther. The lowerAUC valuesof daidzein withEsuggest that L.sporogenes promoted degradation of daidzein att he intestinall evel in favour of othermetabolites(e. g. equol),whosel evelson the otherhand could not achievethe quantification limitduetothe single dose design. Asteady-statestudymayclarifyt his.Onaverage,the formulation containing L.sporogenes showed a moreconstantabsorption thanRa sconfirmed byt he highlyinferiorSEM valuesof EtreatmentAUC compared withR.MRT and t 1/2 valuesof genistein and daidzein justifyt he recommendation of the onceadayr egimen forE.
Phyto-oestrogens
The limitationsof thiss tudyarethe relativelys mall sample size,even though suchadesign isfrequently adopted fort hiskind of products [5, 6] .
The humangut microflorainfluencesthe bioavailability of isoflavones,astheirabsorption occurs in the small intestine wherel ocalm icrobescanh ydrolysesoyisoflavone conjugates,transforming them intothe corresponding bioactiveaglyconesforabsorption ormetabolism [7] .Ani mportantmetaboliteo fd aidzein isequol, exclusivelyproduced byintestinalbacterialmetabolism, and morep otentt hani ts precursordaidzein [8] .The rationale toadd probioticst oi soflavonesist oi ntegrate intestinalm icroflorain ordert oi mprovethe hydrolysis of the isoflavone glyconesand the bioavailability of isoflavones,especiallyw hen the gut microfloraisdepleted duetoantibiotictreatment.Thisw asv alidated byt he results of the presentclinicalp harmacokineticstudy.
Recent in vitro datac learlyindicatethatt he conversion of isoflavonesintoactiveaglyconicformsispromoted by L.sporogenes :incubation of soyisoflavones with L.sporogenes resulted in 98.2%conversion of daidzin tod aidzein and in 87.5 %conversion of genistin to genistein. Inthe absenceof L.sporogenes very poorconversion wasobserved:2.4 %and 2.0%,respectively(data presented byArcoracie tal. att he 81 st Congresof the ItalianSociety of Gynecologyand Obstetrics,20 -24September2 005,B ologna, Italy). Onthe basisof these in vitro data, one would alsoe xpectab eneficial role of L.sporogenes on the conversion of isoflavonest o theiractivef orms in vivo ,especiallyw hen gut microfloraisdepleted duetoantibiotictreatment. Thiss tudyw asperformed tocomplyw iththe recommendation toimproveq uality assuranceand standardisation of food supplements tosupport the claimson contentand bioavailability [9] . 

